cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Viskasari P. Kalanjati
Contact Email
fmi@journal.unair.ac.id
Phone
-
Journal Mail Official
fmi@journal.unair.ac.id
Editorial Address
Folia Medica Indonesiana The Unit of Journal Consortium and Folia Medica Indonesiana Faculty of Medicine, Universitas Airlangga Jl. Prof. Dr. Moestopo No.47, Pacar Kembang, Kec. Tambaksari, Surabaya, Jawa Timur 60132, Indonesia
Location
Kota surabaya,
Jawa timur
INDONESIA
Folia Medica Indonesiana
Published by Universitas Airlangga
ISSN : 23558398     EISSN : 2599056X     DOI : https://doi.org/10.65346/2958-4515.2401
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience
Folia Medica Indonesiana, as indicated by its name, focuses on publishing good quality articles about research and education on health science and medicine in Indonesia. However, due to the fast growth of science and knowledge in these fields, we also welcome submitted articles from around the world, especially the ones that contain related matters from lower-middle income countries. Folia Medica Indonesiana is an open-access, peer-reviewed journal that is published online at least four times a year. The scope covers various aspects of basic medical sciences includes anatomy, physiology, pathology, microbiology, pharmacology, and molecular medicine) and clinical medicine (covers specialties like internal medicine, surgery, pediatrics, oncology, psychiatry, etc). We highlight the pathology and potential treatment of metabolic syndromes and infectious diseases. Folia Medica Indonesiana also encourages the publication of articles about health education. The scope includes, but is not limited to, articles that emphasize on preventive education on certain diseases in a community, also research report of various materials and/or methods to develop medical education. We recognize the importance of this type of articles to be published alongside the assigned topic in each of our yearly issues, to provide our readers with updated information in medical sciences’ research and education simultaneously.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 571 Documents
 9   10   11   12   13 
Anxiety Disorder among Older Adults with Visual Impairment in Ekiti, Nigeria: Implications for the Potential Opportunity to Mitigate the Impact of the Disability and Prevent Psychological Harm Aina, Felix Olukayode; Ajayi, Iyiade Adeseye; Omotoye, Joseph Olusola; Agbesanwa, Tosin Anthony; Dada, Mobolaji Usman; Fadare, Joseph Olusesan; Ajite, Olumide Kayode; Prajjwal, Priyadarshi
Folia Medica Indonesiana Vol. 59, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlights: Anxiety is an important morbidity among visually impaired older adults. There is potential for stakeholders to specifically channel their interventions towards particular IVI domains in order to reduce anxiety prevalence. Abstract: Visual impairment is a significant morbidity among adults globally. It has negative impacts on work force participation and productivity, as and well as higher depression and anxiety disorder rates. In the case of older adults, vision impairment can contribute to social isolation and a greater likelihood of early entry into nursing or care homes. This hospital-based, cross-sectional study was designed to determine anxiety disorder's prevalence among the study population and which Impact of Visual Impairment (IVI) domain is most correlated with anxiety disorder. The study was carried out at the Ophthalmology Clinic of the Ekiti State University Teaching Hospital, Ado Ekiti, Nigera. Questionnaires were used to collect information from 115 respondents. Information sought included sociodemographic information, anxiety status, and visual impairment's impact on daily functions. The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety disorder, while the IVI scale was used to assess the impact of visual impairment. The IVI scale is an instrument used for determining the impact of visual impairment under three domains: (reading and accessing information, mobility and independence, and emotional well-being). Anxiety disorder was detected in 10.4% of all the respondents, and the IVI's mobility and independence domain of IVI was most strongly correlated with anxiety disorder.
Antifungal Activity of Selaginella plana (Desv. ex Poir.) Hieron Extract Against Candida albicans In Vitro Warella, Juen Carla; Rahma, Khairunnida; Widodo, Agung Dwi Wahyu; Setiabudi, Rebekah Juniati
Folia Medica Indonesiana Vol. 59, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlights: 1. A study on the medical benefits of Selaginella plana has significant academic value due to its extensive traditional usage among the Moluccan people as a medicinal remedy, especially for its antifungal properties. 2. The findings of this study will allow further screening to determine the mechanism of action of bioactive compounds in inhibiting the growth of Candida albicans Abstract Candidiasis is an opportunistic infection caused by Candida albicans. This infection commonly affects the skin, oral mucosa, vagina, and gastrointestinal tract. Excessive use of azole antifungals in the treatment of Candida albicans infections can lead to the development of resistance. Therefore, it is necessary to explore alternative treatments using medicinal plants such as Selaginella plana, commonly referred to as "rutu-rutu” in a local language spoken across Maluku, Indonesia. Selaginella plana contains active compounds belonging to various chemical classes, including terpenoids, steroids, flavonoids, and saponins. This study aimed to determine the ability of Selaginella plana extract as an antifungal agent against Candida albicans by evaluating its inhibitory and antifungal effects. This study used an actual experimental design and broth dilution method. The research methodology involved the extraction of Selaginella plana using a solvent of 96% ethanol. The extract was then prepared in various concentrations, i.e., 100%, 50%, 25%, 12.5%, 6.25%, and 3.125%. Additionally, ketoconazole and distilled water were included in the experiment for the positive and negative controls, respectively. The results of this study demonstrated that Selaginella plana extract inhibited the growth of Candida albicans when administered starting at a concentration of 12.5%. However, the antifungal potential of Selaginella plana extract that induced cell death was only observed at a concentration of 100%. The fungicidal activity was exclusively identified in the undiluted, pure extract. The inhibitory and cytotoxic effects of Selaginella plana on Candida albicans cells were attributed to the presence of bioactive compounds in Selaginella plana, including flavonoids, tannins, terpenoids, and saponins. These bioactive compounds had the ability to inhibit cell growth by altering membrane permeability, causing mitochondrial dysfunction, and disrupting ergosterol biosynthesis. It can be concluded that Selaginella plana extract can act as a fungistatic agent against the proliferation of Candida albicans.
COVID-19 Disease Severity and Blood Test Results in Unvaccinated and Vaccinated Patients at Bhayangkara Hospital, Denpasar, Indonesia Muyasaroh, Chanif Lutfiyati; Wiratmini, Ngurah Intan; Sukmaningsih, Anak Agung Sagung Alit
Folia Medica Indonesiana Vol. 59, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlights: This original research report on the differences in disease severity and blood test results between unvaccinated and vaccinated COVID-19 patients is quite novel, as the COVID-19 pandemic was still happening when this study was carried out. This original research report offers information on the advantages of the COVID-19 vaccines and provides data that the public may use as scientific evidence to counter hoaxes. Abstract The COVID-19 pandemic caused by SARS-CoV-2 is an unprecedented event in human history. Vaccines are a safe, long-term solution for addressing the COVID-19 pandemic. This study aimed to investigate the differences in disease severity and blood test results between unvaccinated and vaccinated COVID-19 patients. This study used an analytical observational method with purposive sampling. A total of 90 COVID-19 patients at Bhayangkara Hospital, Denpasar, Indonesia, were divided into three groups: unvaccinated group (V0), two-dose vaccinated group (Vp), and three-dose vaccinated group (Vb). Primary data were collected from July to December 2022, while secondary data were collected from January 2021 to June 2022. The data were analyzed using the Kruskal-Wallis test followed by the Mann-Whitney test, as well as one-way ANOVA test followed by Tukey's honestly significant difference (HSD) test with a confidence interval (CI) of 95% and α of 5%. The results revealed significant differences in disease severity (p<0.001). V0 had a higher percentage of severe (36.7%) and critical (6.7%) symptoms than Vp (severe=10.0%; critical, n=0) and Vb (severe and critical, n=0). The follow-up tests revealed significant differences in disease severity between V0 and Vp (p<0.001), V0 and Vb (p<0.001), as well as Vp and Vb (p=0.001). Blood test results revealed significant differences in lymphocytes (p=0.005), monocytes (p<0.001), monocyte-to-lymphocyte ratio (MLR) (p<0.001), and eosinophils (p=0.037). The follow-up tests revealed significant differences in these four indicators between V0 and Vb, in all parameters except for lymphocytes between V0 and Vp, and in lymphocytes only between Vp vs Vb. In conclusion, unvaccinated patients had a higher percentage of severe and critical symptoms than vaccinated patients. The blood test results revealed significant differences in lymphocytes, monocytes, MLR, and eosinophils. Unvaccinated patients had lower lymphocyte counts, higher MLR levels, and higher monocyte counts than vaccinated patients.
Comparison of PPT and APTT in Pre and Post-Hemodialysis Patients as the Heparin-Exposed Effect Hernaningsih, Yetti; Widodo, Widodo; Aprianto, Koko
Folia Medica Indonesiana Vol. 55, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Evaluations on Plasma Prothrombin Time (PPT) and Activated Partial Thromboplastin Time (APTT) are required in patients with Chronic Kidney Disease (CKD) stage V to determine the risk of bleeding after hemodialysis (HD) using heparin as the anticoagulant. This study aimed to compare the results of PPT and APTT in pre and post-hemodialysis patients with minimum dose of heparin. This was an observational-analytical study with cross-sectional design. The samples were collected in HD wards of Dr. Soetomo Hospital, Surabaya. There were 50 PPT and APTT samples collected from June to August 2017. The samples were evaluated using the tool CoaDATA 501. The examination of coagulation study was conducted in Clinical Pathology Laboratory of Dr. Soetomo Hospital, Surabaya. Paired t-test and Wilcoxon signed-rank test were performed in this study. In the 50 samples, pre-hemodialysis PPT ranged between 10.2-17.6 with the mean of 12.6±2.03 seconds, while for post-hemodialysis, the range was 10.1-20.9 with the mean of 13.41±2.43 seconds. Pre-hemodialysis APPT ranged between 19.5-75.2 with the mean of 30.32±10.43 seconds, while in post hemodialysis the range was 22.21-175 with the mean of 37.52±26.40 seconds. The results of PTT evaluation in pre and post-HD showed no significant difference (p=0.083), while those of APTT showed a significant difference (p=0.035 or p<0.05). Prolongation of APTT in post-HD is due to the use of heparin as an anticoagulant that increases PPT and APTT by inhibiting antithrombin III. HD procedures cause decreased activity of coagulation factors II, IX, X, XII leading to APTT prolongation in post-HD. A significant APTT prolongation was found in post-HD patients with CKD V.
Case Report: Survival of A Coronavirus Disease-2019 (Covid-19) Patient with Acute Respiratory Distress Syndrome (ARDS) in Dr. Soetomo Hospital, Surabaya, Indonesia Soedarsono, Soedarsono; Semedi, Bambang Pudjo; Setiawati, Rosy; Meliana, Resti Yudhawati; Kusmiati, Tutik; Permatasari, Ariani; Bakhtiar, Arief; Syafa'ah, Irmi; Indrawanto, Dwi Wahyu
Folia Medica Indonesiana Vol. 56, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that began in Wuhan, China has spread rapidly in multiple countries of the world and has become a pandemic. Currently, there is no vaccine or specific antiviral for COVID-19. A study reported 7.3% of critical patients admitted to ICU, 71% of them required mechanical ventilation, and 38.5% of them were survived. Herein, we reported a 54 year old man with Acute Respiratory Distress Syndrome (ARDS) of COVID-19 who survived the disease. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasopharyngeal and oropharingeal swabs were positive for SARS-CoV-2. Diagnosis of ARDS was also according to clinical symptoms, laboratory, chest radiograph, and chest CT scan. Alcaligenes faecalis and Candida albicans were also identified from sputum culture. Treatment for this patient was causal and supportive therapy, including antibiotic, antiviral, and antifungal therapy according to the culture results, fluid resuscitation, and oxygen supply from the mechanical ventilator. This patient was survived and discharged on hospital day-29. A fibrosis in parenchyma pulmonary and sensory peripheral neuropathy occurred after survived from ARDS. Monitoring of clinical, laboratory, and chest radiograph were continued after the patient discharged from the hospital. This case highlights the importance of early diagnosis and effective treatment to the care of COVID-19 patient.
The effect of recombinant vascular endothelial growth factor 121 on nitride oxide level in mice (mus musculus) model of preeclampsia Soetrisno, Soetrisno; Isharyadi, Isharyadi; Sulistyowati, Sri
Folia Medica Indonesiana Vol. 53, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Preeclampsia is a multifactorial syndrome in pregnancy whose cause is still unknown. Several proangiogenic and antiangiogenic mediators such as Vascular Endothelial Growth Factor (VEGF) and Nitrite Oxide (NO) play important roles in preventing preeclampsia. VEGF can increase NO level that lowers maternal blood pressure, improves endothelial function and reduces placental hypoxia in preeclampsia. Recombinant VEGF 121 is expected to be an option in the prevention and treatment of preeclampsia. This experimental study used mice (Mus musculus) as the model. The objective of this study was to observe the effect of recombinant VEGF 121 in increasing the level of nitric oxide in mice (Mus musculus) model of preeclampsia. This was an experimental analytical study with Randomized Control Trial (RCT) design. The study enrolled 27 pregnant mice (Mus musculus) which met the restriction criteria divided into 3 groups. The first group (K1) were 9 normal pregnant mice. The second group (K2) were 9 pregnant mice of preeclampsia model without treatment. The third group (K3) were 9 pregnant mice of preeclampsia model receiving recombinant VEGF 121 therapy. The independent variable was the administration of recombinant VEGF 121 and the dependent variable was the serum NO level. Statistical analysis was performed by using anova statistics. NO level in the first group (K1) was 1.746±0.347, with minimum value of 1.00 µM, and maximum value of 2.28 µM, CI (1.479-2.013). NO level in second group (K2) was 1.167±0.380, with minimum value of 0.64 µM, and maximum value of 1.94 µM, CI (0.875-1.460). NO level in the third group (K3) was 2.164±0.556, with minimum value of 1.56 µM, and maximum value of 5.96 µM, CI (1.842-2.486). With anova statistical test, there were significant differences between K1 group and K2 group (p value=0.004<0.05), K1 group and K3 group (p value=0.000<0.05) as well as K2 group and K3 group (p value=0.029<0.05). In conclusion, Recombinant VEGF 121 increased the level of nitric oxide in mice (Mus musculus) model of preeclampsia significantly.
Short-term toxicity test of singalawang extract on male white rats kidney necrosis Naibaho, Ardy Hamonangan; Mustika, Arifa; Rahaju, Anny Setijo
Folia Medica Indonesiana Vol. 52, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Singawalang leaf is used as a traditional medicine by the communities suffering from pneumonia due to TB disease. However, experiments to explain it's toxicity are few. Therefore, this study was conducted to disclose it's toxicity. This was an experimental laboratory study using post–test only control group design. The sampling method was simple random sampling. The animals were randomly divided into 4 (four) groups, each group consisted of 8 (eight) mice, the control group (P0) received distilled water as a solvent material. Treatment group 1 (P1) obtained ethanol extract of singawalang (Petiveria alliaceae) in low doses of 90 mg/kgbw. Treatment group 2 (P2) obtained ethanol extract of singawalang (Petiveria alliaceae) in medium doses of 180 mg/kgbw. Treatment group 3 (P3) obtained ethanol extract of singawalang (Petiveria alliaceae) in high doses of 360 mg/kgbw. Th extracts were given with sonde once a day for 30 days. Results showed that the leaf ethanol extract singawalang (Petiveria alliaceae) does not induce sub-acute necrosis effects on kidney of male white mice (Mus musculus) in doses 90 mg/kgbw, 180 mg/kgbw, and 360 mg/kgbw.
Validity and Reliability of WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) Type 12 Questions Indonesian Version on Back Pain Rijanti, Kusumawardhany Airlangga; Subadi, Imam; Kurniawati, Patricia Maria
Folia Medica Indonesiana Vol. 57, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The study was to prove the validity and reliability of the WHODAS 2.0 Indonesian version questionnaire in patients with back pain. This study was an observational cross-sectional study conducted in 2018. The study included the filling of WHODAS 2.0 Indonesian version, Indonesian version of Oswestry Disability Index (ODI) questionnaire, Wong-Baker Scale, conducted at Department of Rehabilitative Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, against 82 respondents with back pain. Each respondent was given informed consent. The validity of the WHODAS 2.0 Indonesian version questionnaire was measured using Pearson's test on the correlation of WHODAS 2.0 Indonesian version questionnaire and Oswestry Disability Index questionnaire with r >0.3 (0.862). WHODAS 2.0 Indonesian version questionnaire and Wong-Baker Scale had r >0.3 (0.449–0.785). The reliability of the WHODAS 2.0 Indonesian version questionnaire was measured using Pearson's correlation test with r >0.3 (0.764–0.866). WHODAS 2.0 Indonesian version's internal reliability was tested using Cronbach-Alfa Test with alpha >0.6 (0.634–, 853). In conclusion, the WHODAS 2.0 - Indonesian version is a valid and reliable questionnaire for patients with back pain.
The Role of Antiapoptotic Erythropoietin on Ultraviolet B-Induced Photodamaged Skin Through Inhibition of Sunburn Cells Suyono, Handi; Sanjaya, Kristian; Susanti, Deby
Folia Medica Indonesiana Vol. 56, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Ultraviolet light causes photodamaged skin leading to photoaging skin. Ultraviolet-B (UV-B) causes epidermal keratinocyte apoptosis, namely sunburn cell, through apoptotic intrinsic pathway. Erythropoietin (EPO) has a role in cytoprotection in various tissues but its role to epidermal skin is not clear yet. This study was designed pretest-posttest control group design. Thirty two male mice Mus musculus, strain Balbc, were divided into control and treatment group, 16 mice each group. All mice were exposured by UV-B light 16mJ/cm2, distance 30 cm, duration 90 seconds, for 3 consecutive days. Four mice each group were randomly sacrificed as pretest data. The control mice were given aquadest subcutaneous injection 0.1 mL, and treatment mice were given EPO subcutaneous injection 0.1 mL (100 IU/kg BW). UVB were given everyday with same protocol above. Treatments were given 4 times, interval 3 days. All mice were sacrificed to examine sunburn cells. Data were performed as mean ± SD and analyzed by t-test using SPSS 17.0 with significant value p<0.05. Sunburn cells of pretest control were 25.00 ± 4.85% and treatment group were 24.83 ± 5.15%. Sunburn cells significantly decreased (p=0.002) in treatment group (31.5 ± 9.39%) than control (50.83 ± 6.70%). UV-B causes sunburn cells formation. EPO inhibits apoptosis through increasing NO production and eNOS expression, inhibiting caspase and proinflammatory cytokines, and increasing antiapoptotic protein. EPO has a role in skin apoptosis inhibition which is shown by decreased sunburn cells
Analysis of change in nt-probnp after angiotensin receptor blocker (arb) therapy in patient with heart failure Dewi, Intan Kusuma; Aminuddin, Muhammad; Zulkarnain, Bambang Subakti
Folia Medica Indonesiana Vol. 52, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

NT-proBNP is an inactive fragment of BNP secreted by stretched ventricle as response to wall stress in patients with heart failure. As a specific cardiac marker, elevated NT-proBNP correlates well with heart failure severity. The principle of heart failure therapy is modulation on neurohormonal activation. ARB can modulate neurohormon on RAA system, that result in decreasing NT-proBNP level and favorable outcomes. Reduction in NT-proBNP more than biologic variability (> 25%) shows a therapy response.This study was to analyze change of NT-proBNP after ARB therapy in ambulatory HF patients. This observational prospective study was carried from September to December 2015. Blood sampling was performed on patients who meet the inclusion criteria of the study at first visit and after 2 months therapy. NT-proBNP was measured by IMMULITE® as primary parameter and creatinin as secondary parameter. There are 14 patients met the inclusion criteria of the study (11 males and 3 females). ARB therapy used in patients were Valsartan (64%), Telmisartan (22%) and Candesartan (14%). After 2 months ARB therapy, a decrease in level of NT-proBNP with initial median 3092.5 (216 – 32112) pg/ml to 2135.5 (350 – 16172) pg/ml respectively were statistically significant (p=0.003). And the secondary parameter creatinin serum convert to eGFR shows a change in eGFR with initial median 73.33 (37.05 – 266.68) ml/minute to 81.04 (39.31 – 167.02) ml/minute respectively were statistically not significant (p=0.657). There were 7 patients (50%) have a decrease > 25%. In this study, we found that ARB therapy can change NT-proBNP level significantly after 2 months therapy.

Page 11 of 58 | Total Record : 571

 9   10   11   12   13 

Filter by Year

2016 2025


Reset
Filter By Issues
All Issue Vol. 61, No. 2 Vol. 61, No. 1 Vol. 60, No. 4 Vol. 60, No. 3 Vol. 60, No. 2 Vol. 60, No. 1 Vol. 59, No. 4 Vol. 59, No. 3 Vol. 59, No. 2 Vol. 59, No. 1 Vol. 58, No. 4 Vol. 58, No. 3 Vol. 58, No. 2 Vol. 58, No. 1 Vol. 57, No. 4 Vol. 57, No. 3 Vol. 57, No. 2 Vol. 57, No. 1 Vol. 56, No. 4 Vol. 56, No. 3 Vol. 56, No. 2 Vol. 56, No. 1 Vol. 55, No. 4 Vol. 55, No. 3 Vol. 55, No. 2 Vol. 55, No. 1 Vol. 54, No. 4 Vol. 54, No. 3 Vol. 54, No. 2 Vol. 54, No. 1 Vol. 53, No. 4 Vol. 53, No. 3 Vol. 53, No. 2 Vol. 53, No. 1 Vol. 52, No. 4 Vol. 52, No. 3 Vol. 52, No. 2 Vol. 52, No. 1 Vol. 51, No. 4 Vol. 51, No. 3 More Issue